natgillin/translations-raw huggingface dataset:
rilpivirine: If your child is taking rilpivirine, your child’s doctor will monitor your child closely.
Rilpivirin: Če vaš otrok jemlje rilpivirin, bo zdravnik zdravljenje vašega otroka natančno spremljal.
RILUTEK 50 mg film-coated tablets
RILUTEK 50 mg filmsko obložene tablete
RILUTEK 50 mg film-coated tablets riluzole
RILUTEK 50 mg filmsko obložene tablete riluzol
Rilutek is used to extend the patient’s life or to delay the need for mechanical ventilation.
Zdravilo Rilutek se uporablja za podaljševanje življenja bolnika ali časa, ki mu ostane do mehanične ventilacije.
Riluzole Zentiva has not been shown to be effective in the late stages of ALS.
Ni dokazov, da bi zdravilo Riluzol Zentiva bilo učinkovito v poznih stadijih ALS.
Riluzole Zentiva is contraindicated in breast-feeding women (see sections 4.3 and 5.3).
Zdravilo Riluzol Zentiva je kontraindicirano pri ženskah, ki dojijo (glejte poglavji 4.3 in 5.3).
Riluzole Zentiva is not recommended for use paediatric population, due to a lack of data on the safety and efficacy of riluzole in any neurodegenerative diseases occurring in children or adolescents.
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti riluzola, pri katerikoli nevrodegenerativni bolezni otrok in mladostnikov, uporaba zdravila Riluzol Zentiva pri pediatrični populaciji ni priporočljiva.
Riluzole Zentiva is used to extend the patient’s life, or the time before they need to use mechanical ventilation.
Zdravilo Riluzole Zentiva se uporablja za podaljšanje bolnikovega življenja ali podaljšanje časa, preden mora bolnik začeti uporabljati mehansko ventilacijo.
rimiterole and isoprenaline, used to treat respiratory diseases
rimiterol in izoprenalin, ki se uporabljata za zdravljenje bolezni dihal
rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, apomorphine;
rimiterol, izoprenalin, adrenalin, noradrenalin, dopamin, dobutamin, alfa-metildopo, apomorfin;
Rimonabant pharmacokinetics are fairly dose proportional up to about 20 mg.
Farmakokinetika rimonabanta je do približno 20 mg precej sorazmerna odmerku.
Rimonabant should not be used in patients with severe renal impairment (see section 4.2 and 5.2).
Rimonabanta ne smete uporabljati pri bolnikih s hudo okvaro ledvic (glejte poglavji 4.2 in 5.2).
Ringing in ears
zvonjenje v ušesih
ringing in the ear
zvonjenje v ušesih
ringing in the ear,
zvonjenje v ušesih,
Ringing in the ears
zvenenje v ušesih
ringing in the ears
zvenenje v ušesih,
ringing in the ears
zvonenje v ušesih
ringing in the ears
zvonjenje v ušesih
ringing in the ears
zvonjenje v ušesih,
ringing in the ears (normally transient), hearing loss, dizziness
zvonjenje v ušesih (običajno prehodno), izguba sluha, omotica
Ringing in the ears (tinnitus)
zvonjenje v ušesih (tinitus);
ringing in the ears (tinnitus).
zvonjenje v ušesih (tinitus)
Ringing in the ears and deafness are possible side effects.
Zvonjenje v ušesih in gluhost sta možna neželena učinka.
Ringing in the ears and/or feeling a spinning sensation Stomach pain or discomfort, indigestion, dry mouth, or wind
zvenenje v ušesih in/ali občutek vrtenja; bolečina ali neprijeten občutek v trebuhu, prebavne težave, suha usta ali vetrovi.
ringing in the ears feeling foggy in the head
zvonjenje v ušesih, meglen občutek v glavi
ringing in the ears*
zvonjenje v ušesih*,
ringing in the ears,
zvonjenje v ušesih,
Ringing in the ears, ear discomfort
zvonjenje v ušesih, nelagodje v ušesu
ringing in the ears, vertigo
zvonjenje v ušesih, vrtoglavica,
Ringing in the ears;
zvenenje v ušesih,
Ringing in the ears; vertigo
zvonjenje v ušesih, vrtoglavica
Ringing in your ears
zvonjenje v ušes
ringing in your ears
zvonjenje v ušesih
ringing noise in ears
zvonjenje v ušesih
ringing or buzzing in the ears (tinnitus), loss of hearing
zvonjenje ali brnenje v ušesih (tinitus), izguba sluha,
ringing or buzzing in the ears (tinnitus), loss of hearing
zvonjenje ali brnenje v ušesih (tinitus), izgubo sluha,
ringing or buzzing in the ears (tinnitus), loss of hearing
zvonjenje in brenčanje v ušesih (tinitus), izguba sluha
Ringing or buzzing noises in the ear, problems with balance
zvonjenje ali brenčanje v ušesu, težave z ravnotežjem,
Ringing or noise in the ears (tinnitus)
zvenenje ali šum v ušesih (tinitus)
ringing sound in the ears, deafness
zvonenje v ušesih, naglušnost
ringing sound in the ears, ear pain
zvonjenje v ušesih, bolečine v ušesu
ringing sound in the ears, ear pain
zvonjenje v ušesih, bolečine v ušesu,
Ringing sound in your ears
zvenenje v ušesih,
ringing sound in your ears
zvonenje v ušesih
Ringing/sound in the ears (tinnitus)
zvonjenje/zvoki v ušesih (tinitus)
Ringworm, a fungal infection of the skin (tinea versicolor)
lišaj, glivična okužba kože (pityriasis versicolor),
Rinse all the medicine out with warm water.
Izperite vse zdravilo s toplo vodo.
Rinse all the medicine out with warm water.
Zdravilo izperite s toplo vodo.
Rinse and flush procedure, stroke measurement and pump management including troubleshooting
Postopek izpiranja črpalke in katetra, meritev pulznega volumna in upravljanje s črpalko, vključno z odpravljanjem težav.
Rinse it all out with warm water.
Vsega izperite s toplo vodo.
Rinse out your eye with warm water.
Oko izplaknite s toplo vodo.
Rinse the ampoule with these 2 ml and then transfer the rinsing liquid into the diluent.
S tema dvema mililitroma izperite ampulo in nato ta izpirek prenesite v vehikel.
Rinse the mixing bottle, lid, the syringe and plunger under running water. (The mixing bottle may become stained from the medicine.
Mešalno plastenko, zaporko, brizgo in bat sperite pod tekočo vodo. (Mešalna plastenka lahko ostane obarvana zaradi zdravila.
Rinse the mixing bottle, lid, the syringe, and plunger under running water. (The mixing bottle may become stained from the medicine.
Mešalno plastenko, zaporko, brizgo in bat sperite pod tekočo vodo. (Mešalna plastenka lahko ostane obarvana zaradi zdravila.
Rinse the syringe and plunger with clean water.
Brizgo in bat sperite s čisto vodo.
Rinse with water and leave to dry in the air.
Splaknite ju s tekočo vodo in pustite, da se posušita na zraku.
Rinse with water if such contact occurs.
Če pride do stika z njimi, sperite z vodo.
Rinse your eye out with warm water.
Sperite oko s toplo vodo.
Rinse your eye with warm water.
Sperite oko s toplo vodo.
Rinse your hands with large amounts of water
Sperite roke z velikimi količinami vode.
Rinse your mouth with water after every dose and spit it out.
Po vsakem odmerku si usta splaknite z vodo in jo izpljunite.
Rinse your mouth with water after you have used the inhaler.
Po uporabi inhalatorja si mora usta splakniti z vodo.
Rinse your mouth with water after you have used the inhaler.
Po uporabi inhalatorja si usta splaknite z vodo.
Rinsing may reduce the risk of developing oral fungal super-infection during treatment and may also reduce the unpleasant taste associated with colistimethate sodium.
Izpiranje lahko zmanjša tveganje za razvoj ustne glivične superokužbe med zdravljenjem in ublaži neprijeten okus natrijevega kolistimetata.
Rinsing of pump to avoid insulin under-delivery
Izpiranje črpalke za preprečitev nezadostnega dovajanja insulina
Rinsing of the pump
Izpiranje črpalke
Rinsing your mouth out with water immediately after using Revinty Ellipta may help stop this side effect developing.
Nastanek tega učinka lahko pomaga preprečiti izpiranje ust z vodo takoj po uporabi zdravila Revinty Ellipta.
Riociguat
očasno
Riociguat (n=107)
riociguat (n = 107)
Riociguat (n=121)
riociguat (n = 121)
Riociguat (n=150)
riociguat (n = 150)
Riociguat (n=151)
riociguat (n = 151)
Riociguat (n=173)
riociguat (n = 173)
Riociguat (n=52)
riociguat (n = 52)
Riociguat (n=55)
riociguat (n = 55)
Riociguat and its main metabolite are not inhibitors or inducers of major CYP isoforms (including CYP 3A4) or transporters (e.g.
Riociguat in njegov glavni presnovek v terapevtskih plazemskih koncentracijah in vitro ne zavirata ali inducirata glavnih izooblik CYP (vključno s CYP 3A4) ali prenašalcev (npr.
Riociguat CT (n=19)
riociguat CT (n = 19)
Riociguat CT (n=31)
riociguat CT (n = 31)
Riociguat CT (n=32)
riociguat CT (n = 32)
Riociguat CT (n=39)
riociguat CT (n = 39)
Riociguat CT (n=54)
riociguat CT (n = 54)
Riociguat CT (n=58)
riociguat CT (n = 58)
Riociguat CT (n=63)
riociguat CT (n = 63)
Riociguat IDT (n=108)
riociguat IDT (n = 108)
Riociguat IDT (n=123)
riociguat IDT (n = 123)
Riociguat IDT (n=131)
riociguat IDT (n = 131)
Riociguat IDT (n=140)
riociguat IDT (n = 140)
Riociguat IDT (n=232)
riociguat IDT (n = 232)
Riociguat IDT (n=254)
riociguat IDT (n = 254)
Riociguat is cleared mainly via cytochrome P450-mediated (CYP1A1, CYP3A4, CYP2C8, CYP2J2) oxidative metabolism, direct biliary/faecal excretion of unchanged riociguat and renal excretion of unchanged riociguat via glomerular filtration.
Riociguat se odstranjuje iz telesa z oksidativno presnovo, v glavnem preko citokroma P450 (CYP1A1, CYP3A4, CYP2C8, CYP2J2), v nespremenjeni obliki pa z žolčem/blatom in glomerulno filtracijo skozi ledvice.
riociguat is not recommended (see section 4.5);
riociguatom ni priporočljiva (glejte poglavje 4.5);
Riociguat pharmacokinetics are linear from 0.5 to 2.5 mg.
Farmakokinetika riociguata je linearna od 0,5 do 2,5 mg.
Riociguat-treated patients experienced a significant delay in time to clinical worsening versus placebo-treated patients (p = 0.0046; Stratified log-rank test) (see table 6).
Pri bolnikih, zdravljenih z riociguatom, se je čas do kliničnega poslabšanja značilno podaljšal v primerjavi z bolniki, ki so prejemali placebo (p = 0,0046; stratificirani test log-rank) (glejte preglednico 6).
riociguat.
riociguat,
Riom 63963, Clermont Ferrand Cedex 9 France
Riom 63963, Clermont Ferrand Cedex 9 Francija
Riprazo 150 mg film coated tablets are light-pink, biconvex round tablets, imprinted “IL” on one side and “NVR” on the other side.
Riprazo 150 mg filmsko obložene tablete so bikonveksne okrogle tablete svetlo roza barve, z oznako ‘IL’ na eni strani in ‘NVR’ na drugi.
Riprazo 300 mg film coated tablets are light-red, biconvex, ovaloid tablets, imprinted “IU” on one side and “NVR” on the other side.
Riprazo 300 mg filmsko obložene tablete so bikonveksne ovalne tablete svetlo rdeče barve, z oznako ‘IU’ na eni strani in ‘NVR’ na drugi.
Riprazo has been studied in 1,864 patients aged 65 years or older, and in 426 patients aged 75 years or older.
Zdravilo Riprazo so proučevali pri 1.864 bolnikih, starih 65 let ali več, in pri 426 bolnikih, starih 75 let ali več.
Riprazo HCT 150 mg/12.5 mg film-coated tablets are white, oval film-coated tablets imprinted with “LCI” on one side and “NVR” on the other.
Filmsko obložene tablete Riprazo HCT 150 mg/12,5 mg so bele ovalne filmsko obložene tablete z oznako “LCI” na eni strani in “NVR” na drugi.
Riprazo HCT contains lactose (milk sugar).
Zdravilo Riprazo HCT vsebuje laktozo (mlečni sladkor).
Riprazo HCT in combination with an ‘angiotensin converting enzyme (ACE) inhibitors’ or ‘angiotensin receptor blockers’ (ARBs) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Zdravilo Riprazo HCT se v kombinaciji z zaviralcem angiotenzinske konvertaze ali zaviralcem angiotenzinskih receptorjev ne sme uporabljati pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
Riprazo HCT is contraindicated in patients with hypercalcaemia and should only be used after correction of any pre- existing hypercalcaemia.
Zdravilo Riprazo HCT je kontraindicirano pri bolnikih s hiperkalciemijo in ga je mogoče uporabljati šele po korekciji morebitne že prisotne hiperkalciemije.
Riprazo HCT is contraindicated in patients with severe renal impairment or anuria (see section 4.3).
RiprazoRiprazoPri bolnikih s hudo okvaro ledvic in pri bolnikih z anurijo je uporaba zdravila Riprazo HCT kontraindicirana (glejte poglavje 4.3).
Riprazo is not recommended in patients with severe renal impairment (GFR < 30 ml/min/1.73 m2).
Pri bolnikih s hudo okvaro ledvic (GFR < 30 ml/min/1,73 m2) uporaba zdravila Riprazo ni priporočena.
Riprazo may be taken alone or in combination with other medicines for hypertension, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors’ or ‘angiotensin receptor blockers’ (ARBs) in patients with diabetes, or moderate or severe kidney impairment.
Zdravilo Riprazo se lahko jemlje samostojno ali v kombinaciji z drugimi zdravili za zdravljenje hipertenzije z izjemo „zaviralcev angiotenzinske konvertaze (ACE)“ ali „zaviralcev angiotenzinskih receptorjev (ARB)“ pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
Riprazo may be used alone or in combination with other antihypertensive agents with the exception of use in combination with angiotensin converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) < 60 ml/min/1.73 m2) (see sections 4.3, 4.4 and 5.1).
Zdravilo Riprazo se lahko jemlje samostojno ali v kombinaciji z drugimi učinkovinami za zniževanje krvnega tlaka, razen v kombinaciji z zaviralci encima angiotenzinske konvertaze (zaviralci ACE) ali zaviralci angiotenzinskih receptorjev II pri bolnikih s sladkorno boleznijo ali okvaro ledvic (s hitrostjo glomerulne filtracije (GFR) < 60 ml/min/1,73 m2) (glejte poglavja 4.3, 4.4 in 5.1).
rise in body temperature
zvišanje telesne temperature,
Rise in body temperature.
povečanje telesne temperature,
rise in body temperature.
zvišanje telesne temperature,
Rise in white blood cells.
povečanje števila belih krvnih celic
rise in white blood cells; reduction in blood platelets, which increases risk of bleeding or bruising; headache.
zvišanje števila belih krvničk, zmanjšanje števila trombocitov, zaradi česar ste bolj izpostavljeni krvavitvam in modricam, glavobol.
rises in the blood levels of liver enzymes (will show up in blood tests)
povečane vrednosti jetrnih encimov v krvi (pokažejo krvne preiskave)
rises in the blood levels of liver enzymes (will show up in blood tests)
zvišane vrednosti jetrnih encimov v krvi (pokažejo krvne preiskave)
Risk assessment and clinical monitoring are the best indicators of the potential risk of bleeding.
Ocena tveganja in klinično nadziranje sta najboljša napovednika tveganja za morebitno krvavitev.
Risk associated with increased doses of myelosuppressive medicinal products
Tveganja, povezana s povečanimi odmerki mielosupresivnih zdravil
Risk criteria
klasifi- kacija tveganj
Risk diff. (95% CI)
Razlika tveganj (95 % CI)
Risk difference (once daily- twice daily)
Razlika v tveganju (enkrat na dan- dvakrat na dan)
Risk difference (once daily-twice daily)
Razlika v tveganju
Risk difference (once daily-twice daily)
Razlika v tveganju (enkrat na dan-dvakrat na dan)
risk evaluation.
in tveganj.
Risk factor
Dejavnik tveganja
Risk factors associated with ATE, in addition to the underlying malignant disease and age 65 years, included hypertension, diabetes mellitus, and prior thromboembolic disease.
Med dejavniki tveganja, ki so povezani z ATE, so bili poleg osnovne maligne bolezni in starosti  65 let, prisotni hipertenzija, sladkorna bolezen in predhodna trombembolična bolezen.
Risk factors associated with renal impairment/failure in patients receiving sunitinib included, in addition to underlying renal cell carcinoma, older age, diabetes mellitus, underlying renal impairment, cardiac failure, hypertension, sepsis, dehydration/hypovolemia, and rhabdomyolysis.
Dejavniki tveganja, povezani z zmanjšanim delovanjem ledvic/odpovedjo ledvic pri bolnikih, ki so prejemali sunitinib, so poleg predhodno prisotnega karcinoma ledvičnih celic vključevali višjo starost, sladkorno bolezen, predhodno ledvično okvaro, srčno popuščanje, hipertenzijo, sepso, dehidracijo/hipovolemijo in rabdomiolizo.
Risk factors associated with the development of a retinal pigment epithelial tear after anti- VEGF therapy for wet AMD, include a large and/or high pigment epithelial retinal detachment.
Dejavniki tveganja za zatrganje pigmentnega epitelija mrežnice pri zdravljenju vlažne starostne degeneracije makule z zaviralci VEGF sta obsežen in/ali visok odstop pigmentnega epitelija mrežnice.
Risk factors associated with the development of a retinal pigment epithelial tear after anti-VEGF therapy for wet AMD, include a large and/or high pigment epithelial retinal detachment.
Dejavniki tveganja, ki so povezani z nastankom raztrganja pigmentnega epitelija po uporabi zdravil, ki delujejo proti VEGF pri zdravljenju vlažne oblike SDM, vključujejo obsežen in/ali visok odstop pigmentnega epitelija mrežnice.
Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy (see section 4.8).
Predhoden pojav alergije na sulfonamide ali peniciline je lahko dejavnik tveganja za razvoj akutnega glavkoma z zaprtim zakotjem (glejte poglavje 4.8).
Risk factors for developing acute angle- closure glaucoma may include a history of sulfonamide or penicillin allergy.
Med dejavniki tveganja za pojav akutnega glavkoma zaprtega zakotja so lahko alergije na sulfonamide ali penicilin v anamnezi.
Risk factors for developing this disease include: how long you have been taking anti-HIV medicines, whether you take corticosteroids, how much alcohol you drink, how well your immune system works and being overweight.
Dejavniki tveganja za pojav te bolezni vključujejo: čas jemanja zdravil proti virusu HIV, jemanje kortikosteroidov, količino zaužitega alkohola, kako dobro deluje vaš imunski sistem in če imate preveliko telesno maso.
Risk factors for nephrolithiasis include prior stone formation, a family history of nephrolithiasis and hypercalciuria.
Dejavnki tveganja za nefrolitiazo vključujejo predhodni nastanek kamnov, družinsko anamnezo nefrolitiaze in hiperkalciurijo.
Risk factors for oestrogen-dependent tumours, e.g., 1st degree heredity for breast cancer
dejavniki tveganja za nastanek od estrogenov odvisnih tumorjev, npr. dedno nagnjenje za raka dojke v 1. kolenu;
Risk factors for pneumonia in patients with COPD receiving fluticasone furoate/vilanterol include current smokers, patients with a history of prior pneumonia, patients with a body mass index <25 kg/m2 and patients with a (forced expiratory volume) FEV1<50% predicted.
Med dejavniki tveganja za pljučnico pri bolnikih s KOPB, zdravljenih s flutikazonfuroatom/vilanterolom, so trenutno kajenje, predhodna pljučnica v anamnezi, indeks telesne mase < 25 kg/m2 in FEV1 (forsirani ekspiratorni volumen)
Risk factors for thromboembolic disorders (see below)
dejavniki tveganja za trombembolične motnje (glejte spodaj);
Risk factors for TLS include a high tumour burden, high concentrations of circulating cells (≥ 25,000/mm3), hypovolaemia, renal insufficiency, elevated pre-treatment uric acid levels and elevated lactate dehydrogenase levels.
Med dejavniki tveganja za sindrom lize tumorja so veliko tumorsko breme, velika koncentracija celic v obtoku (≥ 25.000/mm3), hipovolemija, insuficienca ledvic, povečana koncentracija sečne kisline pred zdravljenjem in zvišana laktat-dehidrogenaza.
Risk factors for TLS include high tumour burden, preexisting chronic renal insufficiency, oliguria, dehydration, hypotension, and acidic urine.
Med dejavnike tveganja za TLS sodijo velika tumorska masa, obstoječa kronična ledvična insuficienca, oligurija, dehidracija, hipotenzija in kisel urin.
Risk factors related to inhibitor development in this study included non-Caucasian ethnicity, family history of inhibitors and intensive treatment at high dose within the first 20 EDs.
Dejavniki tveganja v tej študiji, povezani z nastankom zaviralcev, so vključevali nekavkaško narodnost, družinsko anamnezo zaviralcev in intenzivno zdravljenje z velikim odmerkom v prvih 20 dneh izpostavljenosti.
Risk factors that may predispose this patient population to increased mortality include age > 65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e.g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines.
Dejavniki tveganja, ki lahko povzročijo večjo dovzetnost te skupine bolnikov za povečano umrljivost, vključujejo starost > 65let, težave s požiranjem, sedacijo, nezadostno prehrano ali dehidracijo, obolenja pljuč (npr. pljučnica, z aspiracijo ali brez nje), ali sočasno uporabo benzodiazepinov.
Risk factors: Thirteen of the 15 subjects in the pazopanib arm of the STS phase III study had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk by increasing cardiac after- load.
Dejavnik tveganja: V študiji III. faze pri STS je imelo v kraku s pazopanibom sočasno hipertenzijo 13 od 15 preiskovancev; hipertenzija je morda poslabšala moteno delovanje srca pri ogroženih bolnikih s povečanjem sistoličnega bremena ("afterload").
Risk Level
velikost tveganja
Risk Management Plan
Načrt upravljanja tveganja (RMP, risk management plan)
Risk Management Plan
Načrt za obvladovanje tveganj (RMP)
Risk Management Plan
Načrt za upravljanje s tveganji
Risk Management Plan
Sistem farmakovigilance
Risk Management Plan ( RMP)
Načrt za obvladovanje tveganja (RMP)
Risk Management Plan (MRP)
Načrt za obvladovanje tveganja (RMP)
Risk Management Plan (RMP)
Načrt obvladovanja tveganja (RMP)
Risk Management Plan (RMP)
Načrt obvladovanje tveganja (RMP)
Risk Management Plan (RMP)
Načrt za obladovanje tveganja (RMP)
Risk Management Plan (RMP)
Načrt za obvladanje tveganja (RMP)
Risk Management Plan (RMP)
Načrt za obvladovanj tveganja (RMP)
Risk Management Plan (RMP)
Načrt zaobvladovanje tveganja (RMP)
Risk Management Plan (RMP)
Vzdrževalno zdravljenje:
Risk Management Plan (RMP) Not applicable
Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
Risk Management Plan (RMP) Not applicable.
Načrt za obvladovanje tveganj (RMP) Navedba smiselno ni potrebna.
Risk Management Plan Not Applicable
Načrt za obvladovanje tveganja (RMP) Navedba smiselno ni potrebna.
Risk Management Plan(RMP)
Načrt za obvladovanje tveganj (RMP)
Risk Management Plan(RMP)
Načrt za obvladovanje tveganja (RMP)
Risk of acute pancreatitis (an inflamed pancreas)
Tveganje za akutni pankreatitis (vnetje trebušne slinavke).
Risk of atrial flutter may be increased in patients receiving class I AADs.,
Tveganje za atrijsko undulacijo je lahko pri bolnikih, ki prejemajo antiaritmike skupine I, povečano.
Risk of cardiac arrhythmias
Tveganje srčnih aritnij
risk of decrease in etravirine
zmanjšanja izpostavljenosti
Risk of glaucoma and blepharitis
tveganje za glavkom in blefaritis
Risk of hyperkaliemia
Tveganje za hiperkaliemijo
Risk of hypertension
tveganje za hipertenzijo
Risk of interactions with other medications
Tveganje medsebojnega delovanja z drugimi zdravili
risk of life-threatening gas embolism if the product is sprayed incorrectly use of pressurized CO2 only
tveganju za življenjsko nevarno zračno embolijo, če se pršilnik nepravilno uporablja, uporabi samo s CO2 pod tlakom,
Risk of medication error due to the availability of two different strengths
Tveganje napake pri odmerjanju zdravila zaradi dveh različnih jakosti.
Risk of mortality among patients who developed ILD on IRESSA or chemotherapy was higher in patients with the following risk factors: smoking, CT scan evidence of reduced normal lung (≤ 50%), pre-existing ILD, older age (≥ 65 years old), and extensive areas adherent to pleura (≥ 50%).
Med bolniki, ki se jim je med zdravljenjem z zdravilom IRESSA ali kemoterapijo pojavila IBP, je bilo tveganje umrljivosti večje, če so imeli naslednje dejavnike tveganja: kajenje, računalniško- tomografske znake zmanjšanja normalnih pljuč (≤ 50 %), že prej obstoječo IBP, višjo starost (≥ 65 let) in obsežne predele adherentne pljučne plevre (≥ 50 %).
Risk of nausea, vomiting, diarrhoea and dehydration
Tveganje navzee, bruhanja, driske in dehidracije
Risk of resistance with undetected HIV-1 infection:
Tveganje za rezistenco pri neodkriti okužbi s HIV–1:
Risk of severe birth defects
Tveganje za hude prirojene napake
Risk of severe birth defects.
Tveganje za hude prirojene napake.
Risk Ratio # (RR; 95% CI)
razmerje tveganja# (RR - risk ratio; 95 % IZ)
Risk ratio & 95%CI
Razmerje tveganja in 95 % IZ
Risk ratio over enoxaparin
Razmerje tveganja glede na enoksaparin
Risk ratio over enoxaparin
Razmerje tveganja glede ne enoksaparin
Risk ratio#
Razmerje tveganja#